Previous Close | 3.6500 |
Open | 3.6100 |
Bid | 4.2200 x 2200 |
Ask | 4.2300 x 800 |
Day's Range | 3.3550 - 3.6700 |
52 Week Range | 0.9200 - 7.8000 |
Volume | |
Avg. Volume | 666,748 |
Market Cap | 221.287M |
Beta (5Y Monthly) | 1.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.8900 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for OMER
SEATTLE, February 20, 2024--Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
In general, high-growth stocks and sleeper stocks under $15 are associated with valuation concerns. Let’s forget inflated giants and overhyped darlings. Today, the article reveals three hidden gems. The three sleeper stocks under $15 I’ll be pointing out today are audacious innovators and may erupt like financial volcanoes by 2029. The first one, a fintech, is shaking up the industry with its revolutionary app, offering everything from student loan refinancing to investing. It capitalizes on con
SEATTLE, February 01, 2024--Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP ("DRI"), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.